Federal Judge Rejects Defendants’ Preemption Defense in Valsartan MDL



DOCUMENTS
  • Order


CAMDEN, N.J. — The New Jersey federal judge overseeing the valsartan multidistrict litigation docket has denied a motion to dismiss filed by drug wholesalers and retailers, ruling that the claims are not preempted by the Drug Supply Chain Security Act (DSCSA) because they do not arise out of any defective tracing.

On Dec. 18, Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey, in addressing an issue of first impression, concluded that the claims allege that the valsartan drugs were contaminated before they entered the supply chain and do not fall under the Act. …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: Navigating Current Mass Tort Litigation

November 30, 2022 - New York, NY
The Knickerbocker

MORE DETAILS



HarrisMartin's Camp Lejeune Litigation Conference: Navigating the Complexities - Where Do We Go From Here?

December 08, 2022 - New York, NY
InterContinental® New York Times Square

MORE DETAILS